Skip to main content

Table 2 Clinicopathologic features, MSI status, and the expression of hMSH2, hMLH1, and p53 protein in type I endometrial carcinomas

From: Microsatellite instability at a tetranucleotide repeat in type I endometrial carcinoma

No.

    

Immunohistochemistry

Tetranucleotide repeat

Mononucleotide repeat

Dinucleotide repeat

Subtype of

 

Age

Stage

Grade

Depth

hMSH2

hMLH1

P53

MYCL1

UT5320

D19S394

D9S242

L17686

D8S321

BAT25

BAT26

BAT40

D17S250

D8S554

D2S123

MSI

1

50

III

2

>50%

+

+

+

H

MSI

H

H

H

H

H

H

H

H

H

H

EMAST

2

67

I

1

<50%

+

+

-

H

H

H

H

H

H

MSI

MSI

H

H

MSI

H

MSI-H

3

56

III

1

<50%

+

+

+

H

H

H

H

H

H

H

H

H

H

H

H

MSS

4

43

I

3

Em

+

+

+

H

H

H

H

H

H

H

H

H

H

H

H

MSS

5

39

II

1

<50%

+

+

-

H

H

H

MSI

H

H

H

H

H

H

H

H

EMAST

6

50

I

1

<50%

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

7

54

I

2

<50%

-

+

-

H

H

H

H

H

H

MSI

H

MSI

H

MSI

MSI

MSI-H

8

40

I

2

<50%

-

-

-

H

H

H

H

H

H

MSI

H

MSI

H

H

H

MSI-H

9

51

I

1

Em

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

10

55

I

1

<50%

-

+

-

MSI

H

H

H

MSI

H

H

H

H

H

H

H

EMAST

11

60

I

1

<50%

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

12

68

III

2

>50%

-

-

-

H

H

H

H

H

H

H

MSI

MSI

H

MSI

H

MSI-H

13

55

I

1

Em

+

+

+

H

MSI

H

H

H

H

H

H

H

H

H

H

EMAST

14

66

I

2

<50%

-

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

15

60

I

2

Em

-

+

-

H

H

H

MSI

H

H

H

H

H

H

H

H

EMAST

16

42

I

1

Em

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

17

53

I

2

Em

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

18

63

I

3

>50%

-

-

+

H

H

H

H

H

H

MSI

H

MSI

H

MSI

MSI

MSI-H

19

58

I

1

Em

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

20

36

I

1

Em

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

21

40

III

1

<50%

+

+

-

H

H

H

H

MSI

H

H

H

H

H

H

H

EMAST

22

68

I

1

<50%

+

-

-

H

H

H

H

H

H

MSI

MSI

MSI

H

H

H

MSI-H

23

41

I

2

Em

+

+

+

H

H

H

H

MSI

H

H

H

H

H

H

H

EMAST

24

50

I

2

<50%

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

25

54

I

1

Em

+

+

-

H

MSI

H

H

MSI

H

H

H

H

H

H

H

EMAST

26

51

I

3

<50%

+

-

-

MSI

MSI

MSI

H

H

H

H

H

H

H

H

H

EMAST

27

63

I

3

Em

+

+

+

H

H

H

H

H

H

H

H

H

H

H

H

MSS

28

46

I

3

Em

+

+

+

H

H

H

H

H

H

H

H

H

H

H

H

MSS

29

64

III

3

>50%

+

+

+

H

H

H

H

MSI

H

H

H

H

H

H

H

EMAST

30

44

II

3

Em

+

+

+

H

H

H

MSI

H

H

H

H

H

H

H

H

EMAST

31

55

III

3

>50%

-

+

+

H

H

H

H

MSI

H

H

H

H

H

H

H

EMAST

32

44

I

1

<50%

-

-

-

H

H

H

H

H

H

MSI

MSI

MSI

MSI

H

MSI

MSI-H

33

43

I

1

<50%

+

+

-

H

H

H

MSI

H

H

H

H

H

H

H

H

EMAST

34

55

I

1

<50%

+

+

+

H

H

H

H

H

H

H

H

H

H

H

H

MSS

35

51

I

1

>50%

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

36

33

I

2

Em

+

+

-

H

H

H

H

H

H

H

H

H

H

H

H

MSS

37

49

I

1

Em

+

-

-

MSI

H

H

MSI

H

H

H

H

H

H

H

H

EMAST

38

52

I

1

<50%

+

+

+

H

H

H

H

H

MSI

H

H

H

H

H

H

EMAST

39

30

I

2

<50%

+

-

-

H

H

H

H

H

H

H

MSI

MSI

MSI

MSI

MSI

MSI-H

  1. Em : Endometrium H: Heterozygosity.
  2. MSS : Microsatellite stable.
  3. MSI : Microsatellite instability.
  4. MSI-H : Microsatellite instability – high frequency.
  5. EMAST : Elevated microsatellite alterations at selected tetranucleotide repeat.
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us